1887

Abstract

. Bloodstream infection is one of the most frequent and challenging hospital-acquired infections and it is associated with high morbidity, mortality and additional use of healthcare resources.

Bloodstream infections have consequences for the patient, such as the evolution to mortality and inappropriate empirical antibiotic prescription, especially when caused by multidrug-resistant Gram-negative bacilli.

. To assess the impact of bloodstream infection and the status of multidrug resistance (MDR) in the evolution of patients who received inappropriate initial antibiotic therapy.

. A retrospective surveillance was conducted on nosocomial bloodstream infections caused by Gram-negative bacilli (GNB) from January 2012 to December 2018 in an adult intensive care unit of a Brazilian tertiary teaching hospital.

. We identified 270 patients with GNB nosocomial bacteremia. Non-survivors were older (with an average age of 58.8 years vs 46.9 years, =<0.0001), presented more severe illnesses, were immunosuppressed (73.7 vs 37.6%, =<0.0001), were more likely to have septic shock (55.8 vs 22.4%, =<0.0001) and had an increased usage of mechanical ventilators (98.6 vs 89.6%, =0.0013) than survivors. In a logistic regression model, inappropriate empirical antibiotic therapy was not an independent predictor of mortality, different from mechanical ventilator (=<0.0001; OR=28.0; 95% CI=6.3–123.6), septic shock (=0.0051; OR=2.5; 95% CI=1.3–4.9) and immunosuppression (=0.0066; OR=2.6; 95% CI=1.3–5.2). In contrast, in a separate model, MDR was strongly associated with the prescription of inappropriate initial antibiotic therapy (=0.0030; OR=5.3; 95% CI=1.7–16.1). The main isolated pathogens were (23.6 %) and (18.7 %). The frequency of MDR organisms was high (63.7 %), especially among non-fermenting bacilli (60.9 %), highlighting (81.6 %) and (41.8 %).

Illness severity (septic shock and immunosuppression) and mechanical ventilation were identified as predictors of mortality. Additionally, MDR was a major determinant of inappropriate antibiotic empirical therapy, but not associated with mortality, and both characteristics were not statistically associated with death.

Funding
This study was supported by the:
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, http://dx.doi.org/10.13039/501100002322 (Award 88882.349889/2019-01)
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001277
2020-12-01
2024-04-25
Loading full text...

Full text loading...

/deliver/fulltext/jmm/70/1/jmm001277.html?itemId=/content/journal/jmm/10.1099/jmm.0.001277&mimeType=html&fmt=ahah

References

  1. Allegranzi B, Pittet D. Preventing infections acquired during health-care delivery. Lancet 2008; 372:1719–1720 [View Article][PubMed]
    [Google Scholar]
  2. Allegranzi B, Bagheri Nejad S, Combescure C, Graafmans W, Attar H et al. Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis. Lancet 2011; 377:228–241 [View Article][PubMed]
    [Google Scholar]
  3. Vilar-Compte D, Camacho-Ortiz A, Ponce-de-León S. Infection control in limited resources countries: challenges and priorities. Curr Infect Dis Rep 2017; 19:20 [View Article][PubMed]
    [Google Scholar]
  4. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:309–317 [View Article][PubMed]
    [Google Scholar]
  5. Stone PW, Braccia D, Larson E. Systematic review of economic analyses of health care-associated infections. Am J Infect Control 2005; 33:501–509 [View Article][PubMed]
    [Google Scholar]
  6. Garrouste-Orgeas M, Timsit JF, Tafflet M, Misset B, Zahar J-R et al. Excess risk of death from intensive care unit-acquired nosocomial bloodstream infections: a reappraisal. Clin Infect Dis 2006; 42:1118–1126 [View Article][PubMed]
    [Google Scholar]
  7. Shorr AF, Tabak YP, Killian AD, Gupta V, Liu LZ et al. Healthcare-associated bloodstream infection: a distinct entity? insights from a large U.S. database. Crit Care Med 2006; 34:2588–2595 [View Article][PubMed]
    [Google Scholar]
  8. Klevens RM, Edwards JR, Richards CL, Horan TC, Gaynes RP et al. Estimating health care-associated infections and deaths in U.S. hospitals, 2002. Public Health Rep 2007; 122:160–166 [View Article][PubMed]
    [Google Scholar]
  9. Vrijens F, Hulstaert F, Van de Sande S, Devriese S, Morales I et al. Hospital-acquired, laboratory-confirmed bloodstream infections: linking national surveillance data to clinical and financial hospital data to estimate increased length of stay and healthcare costs. J Hosp Infect 2010; 75:158–162 [View Article][PubMed]
    [Google Scholar]
  10. Bassetti M, Righi E, Carnelutti A. Bloodstream infections in the intensive care unit. Virulence 2016; 7:267–279 [View Article][PubMed]
    [Google Scholar]
  11. Braga IA, Campos PA, Gontijo-Filho PP, Ribas RM. Multi-hospital point prevalence study of healthcare-associated infections in 28 adult intensive care units in Brazil. J Hosp Infect 2018; 99:318–324 [View Article][PubMed]
    [Google Scholar]
  12. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999; 115:462–474 [View Article][PubMed]
    [Google Scholar]
  13. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118:146–155 [View Article][PubMed]
    [Google Scholar]
  14. Zhang D, Micek ST, Kollef MH. Time to appropriate antibiotic therapy is an independent determinant of postinfection ICU and hospital lengths of stay in patients with sepsis. Crit Care Med 2015; 43:2133–2140 [View Article][PubMed]
    [Google Scholar]
  15. Zilberberg MD, Shorr AF. Appropriate antibiotic treatment in severe sepsis and septic shock: timing is everything. Crit Care Med 2015; 43:2258–2259 [View Article][PubMed]
    [Google Scholar]
  16. Pfaller MA, Carvalhaes CG, Smith CJ, Diekema DJ, Castanheira M. Bacterial and fungal pathogens isolated from patients with bloodstream infection: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (2012–2017). Diagn Microbiol Infect Dis 2020; 97:115016 [View Article]
    [Google Scholar]
  17. Vallés J, Alvarez-Lerma F, Palomar M, Blanco A, Escoresca A et al. Health-care-associated bloodstream infections at admission to the ICU. Chest 2011; 139:810–815 [View Article][PubMed]
    [Google Scholar]
  18. Laupland KB, Lee H, Gregson DB, Manns BJ. Cost of intensive care unit-acquired bloodstream infections. J Hosp Infect 2006; 63:124–132 [View Article][PubMed]
    [Google Scholar]
  19. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34:1589–1596 [View Article][PubMed]
    [Google Scholar]
  20. Kumar A, Ellis P, Arabi Y et al. Cooperative antimicrobial therapy of septic shock database Research Group. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009; 136:1237–1248
    [Google Scholar]
  21. Micek ST, Welch EC, Khan J, Pervez M, Doherty JA et al. Resistance to empiric antimicrobial treatment predicts outcome in severe sepsis associated with Gram-negative bacteremia. J Hosp Med 2011; 6:405–410 [View Article][PubMed]
    [Google Scholar]
  22. Barnett AG, Page K, Campbell M, Martin E, Rashleigh-Rolls R et al. The increased risks of death and extra lengths of hospital and ICU stay from hospital-acquired bloodstream infections: a case-control study. BMJ Open 2013; 3:e003587 [View Article][PubMed]
    [Google Scholar]
  23. Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med 2014; 370:1198–1208 [View Article][PubMed]
    [Google Scholar]
  24. Zilberberg MD, Shorr AF, Micek ST, Vazquez-Guillamet C, Kollef MH. Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study. Crit Care 2014; 18:596 [View Article][PubMed]
    [Google Scholar]
  25. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373–383 [View Article][PubMed]
    [Google Scholar]
  26. CDC - Centers for Disease Control and Prevention National Nosocomial Infection Surveillance System Manual. Department of Health & Human Services. Public Health Service; 1994
  27. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18:268–281 [View Article][PubMed]
    [Google Scholar]
  28. AGÊNCIA NACIONAL DE VIGILÂNCIA SANITÁRIA (BRASIL) – ANVISA Orientações Gerais Para a Implantação Da Sub-Rede Analítica De Resistência Microbiana Em Serviços De Saúde Brasília: ANVISA; 2015
    [Google Scholar]
  29. Akova M, Akan H, Korten V, Biberoğlu K, Hayran M et al. Comparison of meropenem with amikacin plus ceftazidime in the empirical treatment of febrile neutropenia: a prospective randomised multicentre trial in patients without previous prophylactic antibiotics. Int J Antimicrob Agents 1999; 13:15–19 [View Article][PubMed]
    [Google Scholar]
  30. Lodise TP, Patel N, Kwa A, Graves J, Furuno JP et al. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob Agents Chemother 2007; 51:3510–3515 [View Article][PubMed]
    [Google Scholar]
  31. Prowle JR, Echeverri JE, Ligabo EV, Sherry N, Taori GC et al. Acquired bloodstream infection in the intensive care unit: incidence and attributable mortality. Crit Care 2011; 15:R100 [View Article][PubMed]
    [Google Scholar]
  32. Micek ST, Hampton N, Kollef M. Risk factors and outcomes for ineffective empiric treatment of sepsis caused by gram-negative pathogens: stratification by onset of infection. Antimicrob Agents Chemother 2018; 62:e01577–17 [View Article][PubMed]
    [Google Scholar]
  33. Magnason S, Kristinsson KG, Stefansson T, Erlendsdottir H, Jonsdottir K et al. Risk factors and outcome in ICU-acquired infections. Acta Anaesthesiol Scand 2008; 52:1238–1245 [View Article][PubMed]
    [Google Scholar]
  34. Pratikaki M, Platsouka E, Sotiropoulou C, Vassilakopoulos T, Paniara O et al. Risk factors for and influence of bloodstream infections on mortality: a 1-year prospective study in a Greek intensive-care unit. Epidemiol Infect 2009; 137:727–735 [View Article][PubMed]
    [Google Scholar]
  35. Laupland KB, Gregson DB, Zygun DA, Doig CJ, Mortis G et al. Severe bloodstream infections: a population-based assessment. Crit Care Med 2004; 32:992–997 [View Article][PubMed]
    [Google Scholar]
  36. Jiang ZQ, Wang SD, Feng DD, Zhang BX, Mao H et al. Epidemiological risk factors for nosocomial bloodstream infections: a four-year retrospective study in China. J Crit Care 2019; 52:92–96 [View Article][PubMed]
    [Google Scholar]
  37. Esper AM, Moss M, Lewis CA, Nisbet R, Mannino DM et al. The role of infection and comorbidity: factors that influence disparities in sepsis. Crit Care Med 2006; 34:2576–2582 [View Article][PubMed]
    [Google Scholar]
  38. Mayr FB, Yende S, Angus DC. Epidemiology of severe sepsis. Virulence 2014; 5:4–11 [View Article][PubMed]
    [Google Scholar]
  39. Dias VL. Infecções De Corrente Sanguínea Por Bacilos Gram-Negativos Multirresistentes Em Uti De Adultos Mista De Um Hospital Terciário De Ensino No Brasil Dissertação [Mestrado em Imunologia e Parasitologia Aplicadas: Universidade Federal de Uberlândia; 2019
    [Google Scholar]
  40. Reacher MH, Shah A, Livermore DM, Wale MC, Graham C et al. Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis. BMJ 2000; 320:213–216 [View Article][PubMed]
    [Google Scholar]
  41. Carlet J, Ben Ali A, Chalfine A. Epidemiology and control of antibiotic resistance in the intensive care unit. Curr Opin Infect Dis 2004; 17:309–316 [View Article][PubMed]
    [Google Scholar]
  42. Moehring RW, Dyer AP, Dodds Ashley ES. Total duration instead of in-hospital antibiotic days: reaching beyond the hospital walls. Clin Microbiol Infect 2020; 26:268–270 [View Article][PubMed]
    [Google Scholar]
  43. Kiffer C, Hsiung A, Oplustil C, Sampaio J, Sakagami E et al. Antimicrobial susceptibility of Gram-negative bacteria in Brazilian hospitals: the MYSTIC program Brazil 2003. Braz J Infect Dis 2005; 9:216–224 [View Article][PubMed]
    [Google Scholar]
  44. Souli M, Kontopidou FV, Papadomichelakis E, Galani I, Armaganidis A et al. Clinical experience of serious infections caused by Enterobacteriaceae producing VIM-1 metallo-beta-lactamase in a Greek university hospital. Clin Infect Dis 2008; 46:847–854 [View Article][PubMed]
    [Google Scholar]
  45. Baumgart AM, Molinari MA, Silveira AC. Prevalence of carbapenem resistant Pseudomonas aeruginosa and Acinetobacter baumannii in high complexity hospital. Braz J Infect Dis 2010; 14:433–436 [View Article][PubMed]
    [Google Scholar]
  46. Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother 2010; 65:1119–1125 [View Article][PubMed]
    [Google Scholar]
  47. Schaefer MK, Jhung M, Dahl M, Schillie S, Simpson C et al. Infection control assessment of ambulatory surgical centers. JAMA 2010; 303:2273–2279 [View Article][PubMed]
    [Google Scholar]
  48. Boszczowski I, Salomão MC, Moura ML, Freire MP, Guimarães T et al. Multidrug-Resistant Klebsiella pneumoniae: genetic diversity, mechanisms of resistance to polymyxins and clinical outcomes in a tertiary teaching hospital in Brazil. Rev Inst Med Trop Sao Paulo 2019; 61:e29 [View Article][PubMed]
    [Google Scholar]
  49. Vardakas KZ, Rafailidis PI, Konstantelias AA, Falagas ME. Predictors of mortality in patients with infections due to multi-drug resistant Gram negative bacteria: the study, the patient, the bug or the drug?. J Infect 2013; 66:401–414 [View Article][PubMed]
    [Google Scholar]
  50. Battle SE, Bookstaver PB, Justo JA, Kohn J, Albrecht H et al. Association between inappropriate empirical antimicrobial therapy and hospital length of stay in Gram-negative bloodstream infections: stratification by prognosis. J Antimicrob Chemother 2017; 72:299–304 [View Article][PubMed]
    [Google Scholar]
  51. Micek S, Johnson MT, Reichley R, Kollef MH. An institutional perspective on the impact of recent antibiotic exposure on length of stay and hospital costs for patients with gram-negative sepsis. BMC Infect Dis 2012; 12:56 [View Article][PubMed]
    [Google Scholar]
  52. Shorr AF, Micek ST, Welch EC, Doherty JA, Reichley RM et al. Inappropriate antibiotic therapy in gram-negative sepsis increases Hospital length of stay. Crit Care Med 2011; 39:46–51 [View Article][PubMed]
    [Google Scholar]
  53. Maragakis LL, Perencevich EN, Cosgrove SE. Clinical and economic burden of antimicrobial resistance. Expert Rev Anti Infect Ther 2008; 6:751–763 [View Article][PubMed]
    [Google Scholar]
  54. Paul M, Shani V, Muchtar E, Kariv G, Robenshtok E et al. Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents Chemother 2010; 54:4851–4863 [View Article][PubMed]
    [Google Scholar]
  55. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother 2007; 60:913–920 [View Article][PubMed]
    [Google Scholar]
  56. Rossi Gonçalves I, Ferreira ML, Araujo BF, Campos PA, Royer S et al. Outbreaks of colistin-resistant and colistin-susceptible KPC-producing Klebsiella pneumoniae in a Brazilian intensive care unit. J Hosp Infect 2016; 94:322–329 [View Article][PubMed]
    [Google Scholar]
  57. Campos PA. Disseminação De Klebsiella Pneumoniae Multirresistente: Produção De Biofilme, Avaliação Da Virulência E Do Fitness Bacteriano Em Amostras Clínicas Produtoras De Kpc. Tese [Doutorado Em Imunologia E Parasitologia Aplicadas] Uberlândia: Universidade Federal de Uberlândia; 2017
    [Google Scholar]
  58. Rudnick W, Science M, Thirion DJG, Abdesselam K, Choi KB et al. Antimicrobial use among adult inpatients at hospital sites within the Canadian nosocomial infection surveillance program: 2009 to 2016. Antimicrob Resist Infect Control 2020; 9:32 [View Article][PubMed]
    [Google Scholar]
  59. Falcone M, Tiseo G, Antonelli A, Giordano C, Di Pilato V et al. Clinical features and outcomes of bloodstream infections caused by New Delhi metallo-β-Lactamase-producing Enterobacterales during a regional outbreak. Open Forum Infect Dis 2020; 7:ofaa011 [View Article][PubMed]
    [Google Scholar]
  60. Patrier J, Timsit JF. Carbapenem use in critically ill patients. Curr Opin Infect Dis 2020; 33:86–91 [View Article][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001277
Loading
/content/journal/jmm/10.1099/jmm.0.001277
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error